PerkinElmer

JANUARY 25, 2023

Confronting and containing the spread of other infectious diseases like tuberculosis, influenza A and B as well as respiratory syncytial virus (RSV) also remained top global health priorities, as was testing to prevent the transmission of sexually transmitted infections, tickborne diseases and more.

Science 52

Science Laboratories Immune Response Disease 52

Codon

MARCH 24, 2024

market with Wegovy will, by 2030, require about one million liters of production capacity. MenAfriVac is a meningococcal vaccine that remains active, without refrigeration, for up to four days and has significantly boosted vaccine coverage in parts of sub-Saharan Africa. We further estimate that supplying just the U.S.

Engineering 87

Engineering Vaccine Production RNA 87

The Pharma Data

APRIL 22, 2023

Since 1997, WHO and UNICEF have jointly collected information on immunization programmes and vaccine-preventable diseases. Data is gathered annually and used to support important global and regional monitoring and planning functions, as well as track progress towards global and regional indicators.

Vaccine 40

Vaccine Disease 40

The Pharma Data

JUNE 13, 2025

This meant putting the fundamentals of mRNA production directly into the hands of local innovators — a dramatic departure from previous models that kept much of vaccine production within a small number of firms in high-income settings. 2026–2030). mRNA Technology Transfer Programme Moves Into Phase 2.0,

Vaccine 40

Vaccine Production Clinical Trials Science 40

The Pharma Data

FEBRUARY 8, 2021

Vaccines up 14.6%, driven by record demand for differentiated influenza vaccines and continued growth of PPH. to €36,041 million, driven by Dupixent ® (€3,534 million, up 73,9%) and Vaccines. We continue to work in parallel on our two COVID-19 vaccine candidates, with clinical trials starting in the coming weeks.

Vaccine 52

Vaccine Production FDA Pharmaceuticals 52

The Pharma Data

FEBRUARY 4, 2021

Vaccines up 14.6%, driven by record demand for differentiated influenza vaccines and continued growth of PPH. to €36,041 million, driven by Dupixent ® (€3,534 million, up 73,9%) and Vaccines. We continue to work in parallel on our two COVID-19 vaccine candidates, with clinical trials starting in the coming weeks.

Vaccine 52

Vaccine Production FDA Pharmaceuticals 52

The Pharma Data

APRIL 27, 2021

at CER driven by growth drivers Dupixent ® and Vaccines. Vaccines up 5.3%, driven by PPH franchise and demand for influenza vaccines in southern hemisphere. Vaccines delivered growth in its core segments. Rare Disease. Others Rare Disease. Total Rare Disease. Polio/Pertussis/Hib vaccines (incl.

Vaccine 52

Vaccine Production FDA Disease 52

DrugBank

NOVEMBER 4, 2024

trillion loss in GDP by 2030 shows the urgency of this crisis.  This decline in R&D is attributed to scientific challenges associated with identifying new antibiotic targets and the relatively low return on investment compared to other therapeutic areas like oncology or rare diseases.  million deaths associated with it.

Pharmaceutical Companies 98

Pharmaceutical Companies Pharmaceuticals Government DNA 98

The Pharma Data

MAY 4, 2021

Lilly will donate both baricitinib (4 mg tablet) as well as bamlanivimab (LY-CoV555) 700 mg and etesevimab (LY-CoV016) 1400 mg together – providing options to treat COVID-19 patients at different stages of the disease. ” The allocation of therapies will be based on the disease burden and hospitalization rates in each country.

Therapies 52

Therapies Hospitals Treatment FDA Approval 52

The Pharma Data

SEPTEMBER 15, 2020

Next-generation biomarker cytology test supports World Health Organization’s goal to eliminate cervical cancer, which is nearly 100 percent preventable with proper screening, vaccination and treatment. The World Health Organization has set goals for countries to take action to eliminate cervical cancer by 2030.

FDA Approval 52

FDA Approval FDA Laboratories Disease 52

NIH Director's Blog: Drug Development

MAY 15, 2018

Credit: National Institute of Allergy and Infectious Diseases, NIH As a volunteer physician in a small hospital in Nigeria 30 years ago, I was bitten by lots of mosquitoes and soon came down with headache, chills, fever, and muscle aches. In 2016 alone, an estimated 216 million people were treated for the disease.

Drug Development 52

Drug Development Drugs Disease Treatment 52

Codon

NOVEMBER 3, 2024

Physicians working in the early 20th century had little choice but to treat the world’s most rampant infectious disease with methods such as these. Even after microbiologists discovered the bacterium that causes the illness in 1882, it wasn’t until the 1920s that researchers were able to develop a vaccine for TB.

Vaccine 112

Vaccine Trials Therapies Treatment 112

The Pharma Data

APRIL 7, 2021

Thirty of Sanofi’s medicines will be provided across a wide range of therapeutic areas, including cardiovascular disease, diabetes, tuberculosis, malaria and cancer. In December 2020, Sanofi announced it had renewed its five-year partnership with WHO to fight neglected tropical diseases that affect approximately one billion people.

Vaccine 52

Vaccine Packaging Disease Treatment 52

The Pharma Data

JULY 11, 2021

Phase 3 study met primary and secondary endpoints demonstrating MenQuadfi ® induced superior immune responses to serogroup C compared to a standard-of-care vaccine in healthy toddlers MenQuadfi is the first and only quadrivalent ACWY vaccine to demonstrate superior immune response against serogroup C in toddlers.

Immune Response 52

Immune Response Disease Vaccine Licensing 52

The Pharma Data

NOVEMBER 16, 2020

WHO‘s Global Strategy to Accelerate the Elimination of Cervical Cancer, launched today, outlines three key steps: vaccination, screening and treatment. Successful implementation of all three could reduce more than 40% of new cases of the disease and 5 million related deaths by 2050. Cervical cancer is a preventable disease.

Vaccine 40

Vaccine Treatment Disease Engineering 40

The Pharma Data

SEPTEMBER 30, 2021

Boehringer Ingelheim again joins efforts to fight rabies under this year’s theme for World Rabies Day by GARC: “Rabies: Facts, not Fear” Boehringer Ingelheim strives to raise awareness of the disease and its preventio. A disease like rabies, from which we will best protect humans by immunizing animals, is exemplary to spotlight that.

Vaccine 52

Vaccine Government Disease International 52

The Pharma Data

JUNE 5, 2025

A Life-Course Approach to Immunization: Prioritizing Vaccination at Every Age to Unlock the Full Potential of Lifelong Health In a striking demographic milestone, the global population is undergoing a historic transformation: for the first time ever, the number of adults over the age of 65 now exceeds that of children under the age of five.

Vaccine 40

Vaccine Disease Virus Production 40

The Pharma Data

NOVEMBER 12, 2020

Highlighted in a publication by the World Health Organization (WHO) and the United States Centers for Disease Control and Prevention (CDC) , measles cases worldwide increased to 869,770 in 2019, the highest number reported since 1996 with increases in all WHO regions. MCV2 coverage has been steadily increasing but is only now at 71 percent.

Vaccine 52

Vaccine Virus Disease 52

Codon

MARCH 3, 2024

More than 100 billion animals are killed for meat and other animal-derived products every year and there is a staggering number of wild animals that face disease, starvation, and predation in natural and urban environments. Link Making Pan-Vaccines Current vaccines typically offer narrow protection against pathogens, such as influenza.

DNA 103

DNA Engineering Vaccine Virus 103

Codon

MAY 19, 2025

Since 2001, we’ve come a long way toward faster, more effective airborne disease detection. When an infectious disease goes unchecked, each case multiplies exponentially. Currently, we have two primary options for detecting infectious diseases: rapid antigen tests and laboratory-based molecular methods. Queen Mary 2.

Virus 72

Virus RNA Laboratories Hospitals 72

Codon

OCTOBER 27, 2024

The second part — focused on vaccines and medicines — will be published next Sunday, concluding Issue 04 of Asimov Press. ” Doc suffered from tuberculosis, or TB, a bacterial disease caused by Mycobacterium tuberculosis. tuberculosis erupts from the granuloma that it causes active disease. It is not until M.

Immune Response 104

Immune Response Doctors Disease Laboratories 104

Codon

FEBRUARY 23, 2025

Because of PEPFAR’s effectiveness, the United Nations (UN) set an ambitious goal in 2022 to end HIV transmission and eliminate AIDS-related deaths by 2030. For that reason, long-term preventatives are probably a better strategy for controlling the disease. Jerome Horwitz and Wolfram Ostertag.

Clinical Trials 77

Clinical Trials Virus Vaccine DNA 77